NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Index- P/E- EPS (ttm)-0.33 Insider Own93.84% Shs Outstand494.49M Perf Week-61.75%
Market Cap11.35B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float30.48M Perf Month97.53%
Enterprise Value11.34B PEG- EPS next Q- Inst Own0.07% Short Float2.50% Perf Quarter2027.07%
Income-4.30M P/S- EPS this Y- Inst Trans- Short Ratio0.18 Perf Half Y17918.60%
Sales0.00M P/B36.34 EPS next Y- ROA-40.85% Short Interest0.76M Perf YTD17553.85%
Book/sh0.63 P/C1425.69 EPS next 5Y- ROE-42.49% 52W High83.60 -72.55% Perf Year19304.15%
Cash/sh0.02 P/FCF- EPS past 3/5Y-45.88% -60.65% ROIC-52.18% 52W Low0.08 28682.18% Perf 3Y6393.67%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility22.67% 37.30% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM26.73% Oper. Margin- ATR (14)11.64 Perf 10Y-
Dividend Ex-DateFeb 15, 2018 Quick Ratio41.92 Sales Y/Y TTM- Profit Margin- RSI (14)49.02 Recom-
Dividend Gr. 3/5Y- - Current Ratio41.92 EPS Q/Q15.45% SMA20-12.30% Beta2.56 Target Price-
Payout- Debt/Eq0.01 Sales Q/Q- SMA5070.28% Rel Volume0.59 Prev Close23.70
Employees12 LT Debt/Eq0.00 Earnings- SMA200547.52% Avg Volume4.18M Price22.95
IPOJul 16, 2021 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume2,456,208 Change-3.16%
Jun-20-25 03:06AM
Jun-17-25 12:43PM
12:25PM
Jun-16-25 04:30PM
11:00AM
06:01AM Loading…
Apr-30-25 06:01AM
Mar-22-25 11:00AM
Mar-21-25 06:35AM
Mar-17-25 07:28AM
Jul-23-24 04:02PM
Nov-15-23 04:31PM
Jul-31-23 08:15AM
Apr-03-23 07:25AM
Feb-21-23 06:36AM
Nov-21-22 06:49AM
07:55AM Loading…
Nov-15-22 07:55AM
Oct-25-22 06:55AM
Sep-14-22 06:55AM
Sep-12-22 09:15AM
Jun-20-22 05:27AM
May-24-22 05:46AM
May-18-22 08:05AM
06:14AM
May-16-22 08:56AM
Apr-14-22 10:03AM
Apr-07-22 06:09AM
Mar-01-22 08:30AM
Feb-17-22 11:40AM
Feb-16-22 08:42PM
Dec-13-21 08:35AM
08:15AM Loading…
Nov-22-21 08:15AM
08:00AM
Nov-02-21 04:00AM
Oct-19-21 11:44AM
Sep-10-21 06:18AM
02:42AM
Sep-02-21 08:00AM
Aug-20-21 08:00AM
Aug-05-21 08:00AM
Jul-20-21 04:05PM
Jul-16-21 11:43AM
Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.